Novartis Q2 earnings beat estimates on strong performance

Novartis AG (NOVN.SW) reported Q2 FY2026 earnings that beat analyst expectations, with both earnings per share (EPS) and revenue surpassing forecasts. The company reported EPS of 1.9600, compared to an estimated 1.7600, representing a surprise of +11.4%. Revenue came in at 11,701,120,000, exceeding the estimated 11,379,320,000 by 2.8%. These results highlight strong performance in the quarter.

Revenue growth was particularly notable, as the company achieved a 2.8% increase in revenue compared to estimates. This marks a significant improvement from the same quarter last year, when revenue stood at 14,836,000,000. The current quarter’s revenue, while lower than the prior year, still reflects a positive trend in performance and operational efficiency.

The EPS result of 1.9600 was a notable beat, with a 11.4% increase over the estimated 1.7600. This indicates strong profitability and effective cost management. The company’s net income for the same quarter last year was 4,041,000,000, with diluted EPS of 2.06. While the current quarter’s diluted EPS is slightly lower than the prior year, the beat over estimates suggests improved performance relative to expectations.

What it means for markets

The strong Q2 earnings results from Novartis AG are likely to be viewed positively by investors and analysts. The beat in both EPS and revenue indicates that the company is performing well relative to expectations, which could lead to increased investor confidence. These results may also influence broader market sentiment, particularly in the healthcare sector, as they reflect strong performance and effective management of operations.

More Earnings news →